USANA Health Sciences (NYSE:USNA) Upgraded at StockNews.com

StockNews.com upgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a strong-buy rating in a research note published on Saturday morning.

Separately, DA Davidson raised USANA Health Sciences to a “hold” rating in a report on Friday, December 20th.

USANA Health Sciences Price Performance

NYSE USNA opened at $35.29 on Friday. The firm has a market cap of $672.63 million, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. The stock’s 50 day simple moving average is $37.88 and its 200 day simple moving average is $39.84. USANA Health Sciences has a one year low of $31.44 and a one year high of $54.81.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. During the same quarter last year, the firm earned $0.59 EPS. As a group, equities analysts expect that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 675 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.33% of the company’s stock.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently added to or reduced their stakes in USNA. Bank of New York Mellon Corp grew its holdings in USANA Health Sciences by 5.6% in the second quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock worth $4,405,000 after purchasing an additional 5,205 shares during the period. Panagora Asset Management Inc. raised its holdings in shares of USANA Health Sciences by 143.1% in the 2nd quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock worth $1,307,000 after purchasing an additional 16,999 shares during the period. Rhumbline Advisers lifted its position in shares of USANA Health Sciences by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 36,486 shares of the company’s stock valued at $1,651,000 after buying an additional 2,425 shares during the last quarter. Pzena Investment Management LLC lifted its holdings in USANA Health Sciences by 24.4% during the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock valued at $44,183,000 after purchasing an additional 191,289 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in USANA Health Sciences by 26.4% in the 2nd quarter. TD Asset Management Inc now owns 11,500 shares of the company’s stock worth $520,000 after buying an additional 2,400 shares during the period. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.